Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
3 u o# ~6 q# lNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 # o/ i" d% t& W! P) P& A+ b9 h
+ Author Affiliations: i4 v& J7 F4 p9 U' `% }
: A: `" O8 F3 K& S- K
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan " K; {- ?7 r; c$ [
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ( i. F5 I% T1 i' O( k* C- ?& S% R f
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
: N* t0 r7 R% ~ L) w4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 4 J1 Y! J" C- Y) P- L
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan * p/ E. Q& L1 P3 {
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
! k4 `* B! h9 A0 U4 ?% [' t7Kinki University School of Medicine, Osaka 589-8511, Japan ( n1 \3 D- j" T$ h6 z) n% ]# F
8Izumi Municipal Hospital, Osaka 594-0071, Japan ) G# i' ~; q' i$ a
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ' G( Q7 r5 l7 s+ ]
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
& I* }) _3 r. ~$ I; \+ S) sAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
3 T7 y: f9 A/ o" Z- U. T& n3 r C6 d
|